Patent · US Active

Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3

US11155629B2 · kind B2 · utility

1Cited by

94References

20Claims

0Family size

Assignee

AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

Tobias Raum · Munich, DE
Ines Herrmann · Munich, DE
Patrick Hoffmann · Munich, DE
Peter Kufer · Munich, DE
Markus Muenz · Lenggries, DE
Doris Rau · Munich, DE

Key dates

Filing date	Nov 6, 2019
Grant date	Oct 26, 2021
Priority date	—
Expiry date	Dec 26, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.